Evidence map›Paper›PMID 33994432›Full record

ArticleJournal of clinical and experimental hematopathology : JCEH2021

Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2

Katsuhiro Fukutsuka, Futoshi Iioka, Fumiyo Maekawa, Miho Nakagawa, Chiyuki Kishimori, Masahiko Hayashida, Shunsuke Tagawa, Takashi Akasaka, Gen Honjo, Hitoshi Ohno

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and experimental hematopathology : JCEH, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Katsuhiro FukutsukaTenri Institute of Medical Research, Nara, Japan.
Futoshi IiokaDepartment of Hematology, Tenri Hospital, Nara, Japan.
Fumiyo MaekawaTenri Institute of Medical Research, Nara, Japan.
Miho NakagawaTenri Institute of Medical Research, Nara, Japan.
Chiyuki KishimoriTenri Institute of Medical Research, Nara, Japan.
Masahiko HayashidaTenri Institute of Medical Research, Nara, Japan.
Shunsuke TagawaDepartment of Hematology, Tenri Hospital, Nara, Japan.
Takashi AkasakaDepartment of Hematology, Tenri Hospital, Nara, Japan.
Gen HonjoDepartment of Diagnostic Surgical Pathology, Tenri Hospital, Nara, Japan.
Hitoshi OhnoTenri Institute of Medical Research, Nara, Japan.
Tenri Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 62-year-old woman, who had a 16-year history of JAK2

Indexed as

Burkitt LymphomaFemaleHumansHydroxyureaJanus Kinase 2Middle AgedMyeloproliferative DisordersNitrilesPoint MutationPrecursor Cells, B-LymphoidPyrazolesPyrimidinesHydroxyureaJAK2 protein, humanJanus Kinase 2NitrilesPyrazolesPyrimidinesruxolitinibJAK2V617F mutationmyeloproliferative neoplasmprecursor B-cell Burkitt leukemiaruxolitinibt(8;14)(q24;q32)/MYC-IGH

Identifiers

PMID33994432
PMCPMC8265492
OpenAlexW3162773498

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.